Hepatitis B vaccination response of treatment-naive patients with juvenile idiopathic arthritis

Çakmak, Figen; Çakan, Mustafa; Demir, Ferhat; Sönmez, Hafize Emine; Çakmak, Sedat; Demirkan, Fatma Gül; Karadağ, Şerife Gül; Ayaz, Nuray Aktay; Sözeri, Betül

doi:10.1007/s00296-021-04833-3

Cited by 2 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The humoral response to many vaccines may be inadequate and/or their antibody titres may decrease rapidly after vaccination as well [ 7 , 8 ]. In the literature, insufficient serological response to regular vaccines was reported in children with inflammatory diseases [ 9–12 ]. When tested in healthy individuals, the SARS-CoV-2 mRNA vaccine revealed high immunogenicity; however, this study did not involve children with rheumatic diseases [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

Humoral response and safety of BNT162b2 mRNA vaccine in children with rheumatic diseases

et al. 2022

Self Cite

View full text Add to dashboard Cite

Objectives The vaccine represents a cornerstone in tackling the COVID-19 pandemic and with the approval of the BNT162b2 mRNA vaccine in December 2020, it has become a beacon of hope for people around the world, including children. This study aimed to present the data on the humoral response and safety of vaccine in a cohort of patients with pediatric rheumatic diseases (PedRD) receiving immunomodulatory treatments. Methods Forty-one children with PedRD were included and were vaccinated with the BNT162b2 m-RNA vaccine (two doses of 30 µg administered three to four weeks apart). To assess the humoral response, IgG antibodies developed against the S1/Receptor-binding domain (RBD) of the SARS-CoV-2 spike protein at baseline and 3-4 weeks after the second dose were measured. The possible local and systemic side effects and disease activity scores were evaluated during the study period. Results After the second dose of vaccine, markedly elevated anti-RBD IgG titers were observed in all patients with a median titre of 20474 AU/ml (IQ range:6534–36151) with a good safety profile. The median disease duration was 4.3 (IQ: 3.5-5.6) years. In the cohort, 14 (34.1%) received cDMARDs, 16 (39%) received bDMARDs and 11 (26.8%) received a combined therapy (cDMARDs and bDMARDs). Patients treated with combined therapy (median 4695 [IQR:2764-26491]) had significantly lower median titers of anti-RBD IgG than those receiving only cDMARDs. Conclusion PedRD patients receiving immunomodulatory treatments were able to mount an effective humoral response after two dose regimens of BNT162b2 mRNA vaccine safely without interrupting their current treatments.

show abstract

Section: Introductionmentioning

confidence: 99%

Humoral response and safety of BNT162b2 mRNA vaccine in children with rheumatic diseases

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

Mythen in der Kinderrheumatologie – Stimmt es eigentlich, dass…?

Freudenhammer,

Hufnagel

2024

Arthritis und Rheuma

View full text Add to dashboard Cite

ZUSAMMENFASSUNGInfektionen und Impfungen spielen in der Kinderrheumatologie in mehrfacher Hinsicht eine wichtige Rolle und sorgen sowohl bei Kinderärzten als auch bei Eltern regelmäßig für Verunsicherung. So wird gemeinhin davon ausgegangen, dass Patienten mit rheumatischen Erkrankungen, insbesondere unter antirheumatischer Medikation, eine erhöhte Anfälligkeit für Infektionen aufweisen. Daher kommt insbesondere Impfungen zur Prävention von Infektionen eine zentrale Rolle zu. Gleichzeitig würden die meisten Kinderrheumatologen aus Erfahrung wohl zustimmen, dass Infektionen oder Impfungen Schübe triggern können. Und dann kommt Infektionen nach der Hygienehypothese sogar möglicherweise eine präventive Funktion zu…? Einige der verbreiteten Annahmen werden im vorliegenden Artikel etwas genauer unter die Lupe genommen und auf ihre Evidenz hin überprüft

show abstract

Hepatitis B vaccination response of treatment-naive patients with juvenile idiopathic arthritis

Cited by 2 publications

References 31 publications

Humoral response and safety of BNT162b2 mRNA vaccine in children with rheumatic diseases

Humoral response and safety of BNT162b2 mRNA vaccine in children with rheumatic diseases

Mythen in der Kinderrheumatologie – Stimmt es eigentlich, dass…?

Contact Info

Product

Resources

About